Medplus Health Services Limited has informed the Exchange about Investor Presentation
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus reported Q1 FY2026 revenue of ₹15,426m, up 3.6% year-on-year but only 2.2% quarter-on-quarter. Gross margin stood at 26.1%, up 400 bps YoY but down 40 bps QoQ. Operating EBITDA came in at ₹728m (4.7% margin), up 67.5% YoY but down 9.4% QoQ, while PAT was ₹423.4m, up 195.2% YoY but down 17.5% QoQ. The company added 101 net new stores (124 openings), taking the total to 4,813 stores across 13 states. Same-store (>12 months) revenue saw a slight 0.2% decline, though mature store-level EBITDA margin held at 10.9% with a healthy 59.8% store-level operating ROCE. Free cash flow was strong at ₹1,072m, with a closing cash balance of ₹5,549m and net working capital improving to 59 days.
The sequential decline in EBITDA and PAT, combined with marginal same-store revenue degrowth, may concern investors looking for consistent quarterly momentum. However, strong cash generation, healthy store-level returns, and continued network expansion support the long-term growth story. Near-term stock reaction may be muted given the mixed QoQ trends.